Ziopharm concludes enrollment in IL-12 & nivolumab combination trial
Category: #health  By Mateen Dalal  Date: 2019-06-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

Ziopharm concludes enrollment in IL-12 & nivolumab combination trial

Controlled IL-12 platform from Ziopharm is an investigational gene therapy designed to control and induce human interleukin 12 production

Ziopharm Oncology Inc, a company that focuses on developing cell therapies and immune-oncology gene, recently announced that they have completed enrolling for third cohort of Phase 1 clinical study to evaluate Controlled IL-12 combined with the PD-1 inhibitor OPDIVO (nivolumab) to treat progressive or recurrent glioblastoma multiforme (rGBM) in adult subjects.

Investigators who will conduct this multi-central trial at the University of Texas MD Anderson Cancer in Houston, Brigham and Women’s Hospital in Boston and Northwestern university in Chicago, have expressed their interest in expanding the study. Based on the final agreement done by the Data and Safety Monitoring Board, the company expects to enroll more patients for the highest dosing level.

Ziopharm’s Chief Executive, Laurence Cooper M.D., Ph.D., said that the company has completed the enrollment of the escalated dose: Ad-RTS-hIL-12+ veledimex along with nivolumab and further explored the potential for the expansion of this combination trial which can enhance their clinical experience.

There is a clear enthusiasm to combine PD-1 inhibitors with IL-12 in the ongoing study and the company is looking forward to starting a phase 2 trial that includes Ad-RTS-Hil-12 + veledimex as well as cemiplimab in the future, Cooper informed.

Citing reliable sources, the Controlled IL-12 platform of Ziopharm is reportedly an investigational gene therapy that is designed to specifically control and induce the human interleukin 12 production, the immune system’s master-regulator. Set in the rGBM, the company has reportedly leveraged anti-tumor effects as monotherapy for Controlled IL-12 with the combination of PD-1 inhibitors.

Apparently, there was a report previously that had a data of patients suffering from serial biopsies with rGBM, which showed that Controlled IL-12 results in upregulation of PD-1 expression and sustained influx of T cells, all of which provides an intriguing rationale for the combination.

Seemingly, it is anticipated that Ziopharm shall report more data from the combination trial at medical meetings this year and into the next.

 

Source Credits- https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-completes-enrollment-controlled-il-12-plus

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

AbbVie buys Mavupharma to target STING pathway for cancer treatment
AbbVie buys Mavupharma to target STING pathway for cancer treatment
By Mateen Dalal

AbbVie Inc., a US-based pharmaceutical company recently announced acquisition of Mavupharma, a Seattle-based biopharmaceutical company, which is focused on innovative strategies to target the STimulator of INterferon Genes pathway for the treatment o...

Motorola Solutions buys WatchGuard to expand video security portfolio
Motorola Solutions buys WatchGuard to expand video security portfolio
By Mateen Dalal

WatchGuard’s solutions allow law enforcement users to manage high-quality video evidence Motorola Solutions, Inc., the US based data communications and telecommunications equipment provider, has recently announced the acquisition of WatchGuard...

Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
By Mateen Dalal

The study is formulated to evaluate the safety and efficacy of Oral KORSUVA for moderate to severe pruritus Biopharmaceutical firm Cara Therapeutics Inc. has reportedly announced the initiation of their Phase 2 trial of Oral KORSUVATM for pruritus t...